Pozen patents possibly prevent Par push for generic Treximet
This article was originally published in Scrip
Executive Summary
Pozen has filed a motion in a federal court to prevent generics maker Par Pharmaceutical from launching a generic version of its migraine combination treatment, Treximet (sumatriptan and naproxen sodium), in the US marketplace. Treximet is marketed in the US by GlaxoSmithKline.